AI assistant
Acticor Biotech — Share Issue/Capital Change 2022
Jun 7, 2022
1070_dva_2022-06-07_44435353-7b54-4b59-bc64-5fe6c8a64e60.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disclosure of the total number of voting rights and shares as of May 31, 2022
COMMUNIQUÉ DE PRESSE
Paris, France, June 7, 2022 - ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of May 31, 2022 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).
- Listing Place : Euronext Growth Paris
- ISIN Code : FR0014005OJ5
- Web site: acticor-biotech.com
| Date | Number of shares making up the share capital |
Theoretical number of voting rights(1) |
Number of voting rights excluding shares stripped of voting rights (2) |
|---|---|---|---|
| May 31, 2022 | 10.545.776 | 10.545.776 | 10.502.986 |
- (1) In accordance with Article 223-111 of the AMF's General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
- (2) The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.
Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.
Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR0014005OJ5 – ALACT).
For further information, please go to www.acticor-biotech.com
Contacts
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
[email protected] T. : +33 (0)6 76 23 38 13
Sophie BINAY, PhD
NewCap Mathilde BOHIN / Olivier BRICAUD Investor Relations [email protected] T. : +33 (0)1 44 71 94 95
General Manager and CSO [email protected] T. : +33 (0)6 76 23 38 13